Table 2.
Study | Inclusion/exclusion criteria specified | Non-biased selection | Missing value/loss to follow-up considered | Modelling assumptions satisfied | Model external validation | Outcome assessed without knowledge of the candidate predictors (ie, blinded) | Duration of follow-up long enough | Potential clinical use of the model discussed | Study limitations discussed |
Yang et al 38 | Yes | Yes | Not clear | No | No | Not clear | Yes | Yes | Yes |
Kothari et al 21 | Yes | Yes | No | Yes | Yes | Not clear | Yes | Yes | Yes |
Wells et al 47 | Yes | Yes | Yes | No | No | Not clear | No | Yes | Yes |
Stevens et al (UKPDS 66)24 | Yes | Yes | Not clear | No | No | Yes | Yes | Yes | No |
Tanaka et al (JJ Risk Engine)48 | Yes | Yes | Yes | No | No | Not clear | Yes | No | Yes |
Palmer et al (IRS)23 | Yes | Not clear | No | No | No | Not clear | Yes | No | Yes |
Kiadaliri et al 22 | Yes | Yes | Yes | No | No | Not clear | No | No | Yes |
Li et al 49 | Yes | Yes | Yes | Yes | No | Not clear | Yes | Yes | Yes |
Basu et al RECODe36 | Yes | Yes | No | Not clear | Yes | Not clear | No | Yes | Yes |
IRS, inflammatory risk score; JJ, The JDCS/J-EDIT; RECODe, Risk Equations for Complications of Type 2 Diabetes; UKPDS, United Kingdom Prospective Diabetes Study.